Angirid Mr 35 MG


Angirid Mr 35 MG


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)



Trimetazidine Dihydrochloride



Adults should use Trimetazidine Dihydrochloride as an add-on medication for the symptomatic treatment of stable angina pectoris who are not responding to or are intolerant to first-line antianginal treatments.



Trimetazidine Dihydrochloride is the primary 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic specialist with demonstrated benefits for all coronary patients. Trimetazidine Dihydrochloride hinders greasy corrosive pathway by hindering 3-keto acyl CoA thiolase chemical and exchanges oxygen to glucose pathway. Since glucose pathway is more proficient in creating vitality, the same oxygen produces more vitality and makes the heart more dynamic. In addition, the oxygen consuming oxidation of glucose stops generation of lactic corrosive, which anticipates angina pectoris.


Dosage & Administration

The recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.



So yet, no medication interactions have been observed. Beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic medicines, and digitalis preparation have all been documented to have no interactions.



Patients who are hypersensitive to the active ingredient or any of the excipients should avoid using trimetazidine. It’s also not recommended for people who have Parkinson’s disease, parkinsonian symptoms, tremors, restless legs syndrome, or significant renal impairment.


Side Effects

Trimetazidine is a drug that is both safe and well tolerated. Dizziness, headache, stomach discomfort, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria, and asthenia are all common adverse effects of Trimetazidine.


Pregnancy & Lactation

There is no information about Trimetazidine’s use in pregnant women. In terms of reproductive toxicity, animal studies show no direct or indirect adverse consequences. It is advised to avoid using Trimetazidine during pregnancy as a preventative measure. Trimetazidine is not known to be excreted in human milk. A risk to neonates and infants cannot be ruled out. Breast-feeding mothers should avoid taking trimetazidine.


Precautions & Warnings

Trimetazidine is neither a cure for angina episodes, nor is it a first-line treatment for angina pectoris. It also isn’t used to treat myocardial infarction.


Therapeutic Class

Other Anti-anginal & Anti-ischaemic drugs


Storage Conditions

Keep away from light and heat in a dry location. Keep out of children’s reach.


Pharmaceutical Name

ACME Laboratories Ltd.